Pyronaridine - Armaceutica
Alternative Names: Pyronalidine tetraphosphateLatest Information Update: 08 Dec 2022
Price :
$50 *
At a glance
- Originator Armaceutica
- Class Acridines; Antimalarials; Antineoplastics; Chlorinated hydrocarbons; Ethers; Naphthyridines; Pyrrolidines; Small molecules
- Mechanism of Action Apoptosis stimulants; Cell cycle inhibitors; Cell cycle stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Clinical Phase Unknown Breast cancer; Liver cancer; Lung cancer; Ovarian cancer
- Preclinical Lymphoma
Most Recent Events
- 21 Nov 2022 Phase-II clinical trials in Acute myeloid leukaemia (Adjunctive treatment, First-line therapy) in Senegal (PO) (NCT05291390)
- 21 Nov 2022 Phase-II clinical trials in Precursor cell lymphoblastic leukaemia-lymphoma (Adjunctive treatment, First-line therapy) in Senegal (PO) (NCT05291390)
- 06 Apr 2022 Clinical trials in Breast cancer in USA (PO) (Armaceutica website, March 2022)